Here are 1-3 brief analogies to describe Palatin Technologies (PTN):

• The Pfizer of women's sexual health.
• Like Vertex Pharmaceuticals, but focused on inflammatory and ocular conditions.

```html

• Vyleesi: A melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
• PL8177: An oral, selective MC1r agonist peptide undergoing development for inflammatory bowel diseases.
• PL9643: A peptide melanocortin agonist targeting MC1r and MC5r for anti-inflammatory ocular indications, including dry eye disease.
• Melanocortin peptides for diabetic retinopathy: A class of peptides under development for treating diabetic retinopathy.
• PL3994: A natriuretic peptide receptor (NPR)-A agonist for various cardiovascular indications.
• PL5028: An NPR-A and NPR-binder designed to treat cardiovascular and fibrotic diseases.

```

Palatin Technologies (PTN) is a biopharmaceutical company that develops and seeks to commercialize prescription therapeutics. As such, its primary customers are other companies (B2B) within the pharmaceutical and healthcare industry, rather than individual consumers. The provided background information does not disclose the specific names of Palatin Technologies' major customer companies. However, based on its business model and the nature of prescription drug commercialization, its customers would typically be entities involved in the distribution and sales of pharmaceuticals. These generally include:

• Pharmaceutical wholesalers and distributors, which purchase drugs from manufacturers and supply them to pharmacies, hospitals, and other healthcare providers.
• Other pharmaceutical or biotechnology companies, which may enter into licensing agreements or partnerships with Palatin Technologies for the further development, marketing, and sales of its drug candidates (such as Vyleesi or pipeline products).
• Large pharmacy chains or integrated healthcare systems, which might engage in direct purchasing agreements with the manufacturer for specific products.

• AGC Biologics
• Ajinomoto Co. Inc. (TSE: 2802, OTC: AJINY)

Carl Spana, Ph.D., Chief Executive Officer, President, and Director

Dr. Spana co-founded Palatin Technologies in 1986 and has served as its Chief Executive Officer and President since June 2000. He has been a director of Palatin since June 1996. Before his tenure as CEO, he was an executive vice president and chief technical officer from 1996 to 2000. Prior to joining Palatin, Dr. Spana was Vice President of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and The Castle Group Ltd., a medical venture capital firm, from 1993 to 1996. Through these roles, he co-founded and acquired several private biotechnology firms. He also worked as a research associate at Bristol-Myers Squibb from 1991 to 1993. Dr. Spana holds a Ph.D. in molecular biology from The Johns Hopkins University and a B.S. in biochemistry from Rutgers University.

Stephen T. Wills, CPA, MST, Chief Financial Officer, Chief Operating Officer, Treasurer, and Secretary

Mr. Wills has served as Palatin Technologies' Chief Financial Officer since November 1997 and as Chief Operating Officer since June 2011. He has held various roles at Palatin since 1997, including Executive Vice President of Operations from 2005 to 2011. Mr. Wills previously served as an Executive Chairman and Interim Principal Executive Officer at Derma Sciences, Inc. from 2015 to 2017, where he was also Chief Financial Officer from 1997 to 2000. He was President and Chief Operating Officer of Golomb, Wills & Company P.C. from 1991 to 2000. Mr. Wills has a track record of involvement with companies that have been acquired, including serving on the board of Gamida Cell Ltd., which was acquired by Highbridge Capital Management in 2024, and Amryt Pharma, acquired by Chiesi Farmaceutici in 2023. He also served as CFO of Cactus Acquisition Corp, a Special Purpose Acquisition Company. Mr. Wills is a Certified Public Accountant and holds a B.S. in Accounting from West Chester University and an M.S. in Taxation from Temple University.

Michael B. Raizman, M.D., Chief Medical Officer

Dr. Raizman was appointed Chief Medical Officer of Palatin in 2021. In this role, he leads and directs the company's product pipeline, including clinical validation, medical, and regulatory affairs. Dr. Raizman is also a physician with Ophthalmic Consultants of Boston and serves as an Associate Professor of Ophthalmology at Tufts University School of Medicine. He received his medical training from Harvard Medical School and the University of Michigan.

James E. Hattersley, Senior Vice President, Business Development

Mr. Hattersley joined Palatin in June 2021 as Senior Vice President of Business Development. He brings over 25 years of experience in product acquisitions, corporate alliances, and business and corporate development, overseeing all business development strategies for Palatin's programs. Mr. Hattersley earned his M.S. in Biochemistry and B.A. in Neurobiology from the University of California, Santa Cruz.

John Dodd, Ph.D., Senior Vice President, Preclinical Development

Dr. Dodd serves as the Senior Vice President of Preclinical Development at Palatin Technologies, where he is responsible for guiding the company's preclinical research efforts.

There are several key risks to Palatin Technologies (PTN):

1. Commercialization and Market Acceptance Risk for Vyleesi: Palatin's lead product, Vyleesi, is already marketed for premenopausal women with hypoactive sexual desire disorder. A significant risk is its ability to achieve sufficient market penetration, physician adoption, and patient acceptance to generate meaningful revenue. Factors such as competition, physician prescribing habits, patient awareness, and insurance coverage could hinder its commercial success and significantly impact the company's financial performance.
2. Clinical Development and Regulatory Approval Risk for Pipeline Products: The company has a substantial pipeline of drug candidates (e.g., oral PL8177, PL9643, melanocortin peptides for diabetic retinopathy, PL3994, PL5028) in various stages of development, from Phase I to earlier stages. All these candidates face inherent risks associated with clinical trials, including potential failures in demonstrating efficacy or safety, unexpected adverse events, or delays in trial completion. Failure to successfully complete clinical trials or obtain regulatory approvals for these pipeline products would limit the company's future growth prospects and could require substantial additional investment without a clear return.
3. Funding and Liquidity Risk: As a biopharmaceutical company with an active R&D pipeline, Palatin Technologies requires significant capital to fund ongoing clinical trials, research and development activities, and commercialization efforts for Vyleesi. The company's ability to continue operations and advance its pipeline is dependent on its capacity to secure additional funding through equity financing, debt, partnerships, or revenues from Vyleesi. Insufficient funding could lead to delays, suspension, or termination of development programs.

null

Palatin Technologies, Inc. develops targeted receptor-specific therapeutics for various diseases. The addressable markets for its main products and pipeline candidates include:

• Vyleesi (bremelanotide) for Hypoactive Sexual Desire Disorder (HSDD): The global hypoactive sexual desire disorder treatment market size was valued at USD 2.7 billion in 2025 and is projected to reach USD 4.0 billion by 2034. The North American female sexual dysfunction treatment market, which includes HSDD, is projected to reach USD 782.3 million by 2032 in the U.S.
• Oral PL8177 for Inflammatory Bowel Diseases (IBD): The global inflammatory bowel disease treatment market size was approximately USD 26.6 billion in 2024 and is expected to grow to USD 47.3 billion by 2034. The North American market for inflammatory bowel disease treatment was valued at USD 12.72 billion in 2025, with the U.S. market reaching USD 16.6 billion in 2024.
• PL9643 for Dry Eye Disease: The global dry eye disease market size is estimated to be valued at USD 7.33 billion in 2024 and is expected to surpass USD 13.26 billion by 2031. The North American dry eye syndrome market size was valued at USD 3.76 billion in 2025, and the U.S. market is projected to reach USD 5.60 billion by 2032.
• Melanocortin peptides for Diabetic Retinopathy: The global diabetic retinopathy market size is calculated at USD 10.23 billion in 2025 and is predicted to increase to approximately USD 18.93 billion by 2035. North America held a significant share of this market, with 38% in 2025.
• PL3994 and PL5028 for Cardiovascular Indications: The global cardiovascular treatment market size was estimated at USD 241.18 billion in 2024 and is projected to reach USD 383.11 billion by 2033. North America dominated the global market in 2024.
• PL5028 for Fibrotic Diseases: The global fibrotic diseases treatment market is expected to reach USD 10.35 billion by 2032, growing from USD 5.79 billion in 2024.

Palatin Technologies (PTN) is poised for future revenue growth over the next 2-3 years, primarily driven by contingent milestone payments from its divested product, and the continued development and out-licensing of its advanced pipeline assets in dry eye disease, ulcerative colitis, and obesity.

1. Contingent Milestone and Royalty Payments from Vyleesi: Although Palatin Technologies sold the worldwide rights for Vyleesi to Cosette Pharmaceuticals in December 2023, the company remains eligible for significant sales-based milestone payments, potentially totaling up to $159 million, contingent on Vyleesi achieving specific annual net sales thresholds. These payments represent a potential non-product revenue stream tied to Vyleesi's commercial success.
2. Licensing and Milestone Payments from PL9643 for Dry Eye Disease (DED): Palatin's PL9643 has shown positive Phase 3 results in dry eye disease, demonstrating rapid efficacy and symptom resolution. The FDA has confirmed the acceptability of the remaining Phase 3 clinical trials, with topline results expected by year-end 2025 and an NDA submission anticipated in the first half of calendar year 2026. An initial sublicensing agreement for PL9643 with Altanispac Labs in January 2026 generated approximately $3.8 million in upfront consideration to be recognized as licensed revenue. Further successful development and potential additional partnerships in the large and growing DED market are expected to drive future revenue through upfront payments, milestones, and royalties.
3. Upfront and Milestone Payments from Partnerships for the Melanocortin Receptor Agonist Pipeline: Palatin is actively developing and seeking partnerships for several other melanocortin receptor agonist programs. This includes PL8177 for ulcerative colitis, which announced positive Phase 2 topline results in March 2025, leading to ongoing licensing discussions with multiple pharmaceutical companies that could result in significant upfront and milestone payments. Additionally, the company is focusing on its obesity pipeline, with the lead oral molecule PL7737 (a melanocortin-4 receptor agonist) on track for IND submission and Phase 1 trials in the first half of 2026. Progress in the male sexual dysfunction program, with Phase 2/3 results targeted for the first half of 2026, could also lead to future licensing opportunities.

Share Issuance

• Palatin Technologies completed an upsized $18.2 million underwritten public offering on November 12, 2025.
• The number of shares outstanding for PTN increased by 232.53% in one year.
• Shares outstanding were 0.97 million at the end of 2025, 0.41 million in 2024, and 0.28 million in 2023, reflecting significant share issuance.

Inbound Investments

• In August 2025, Palatin Technologies entered an agreement with Boehringer Ingelheim International GmbH, which acquired certain patent applications for melanocortin receptor-targeted peptides.
• Under the Boehringer Ingelheim agreement, Palatin received an upfront payment of $2.3 million in September 2025 and may receive up to $21.2 million in near-term research milestone payments and up to $307 million in success-based development, regulatory, and commercial milestone payments.
• Palatin received a $3.8 million upfront payment from sublicensing PL9643 to Altanispac Labs.

Capital Expenditures

• Capital expenditures in the most recent quarter totaled -$0.01 million USD.
• In the last 12 months, capital expenditures were -$12,816.
• Cash flow forecasts indicate very low capital expenditures, with a CAPEX of 0.00572 and 0.2614, showing a significant percentage change but small absolute values.